Mosha east palace neck cancer vaccine is on the market! There are 11 pharmaceutical companies in line

Source: sepiland, 2017-11-10 medical network, November 10 following GlaxoSmithKline's Hirsch, the second cervical cancer vaccine in China's mainland market, Merck East four price jiadaxiu, has opened appointments in some provinces and cities, at least 32.2 billion mainland markets, and the smoke of gunpowder is beginning to rise Needless to say, 11 domestic pharmaceutical companies have submitted clinical applications for cervical cancer vaccine, and the nine price vaccine of mosadong, which is under review Recently, according to media reports, at the beginning of November, four price cervical cancer vaccine (hereinafter referred to as "four price HPV vaccine") was officially listed in the mainland and successively entered the bidding and procurement channels of various provinces According to cerberyl, at present, only the cervical cancer vaccines of GlaxoSmithKline and MSD have been approved for marketing in the world, and the four price, nine price and two price of GlaxoSmithKline have been approved for marketing Sabilan also learned that the four price HPV vaccine of moshadong has started to participate in bidding in various regions, and has won the bid in six provinces including Yunnan, Chongqing, Henan, Jiangxi, Hubei and Heilongjiang, with a price of 798 yuan / piece ▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍▍、▍▍▍▍▍ According to popular saying, "the higher the price is, the better the prevention effect is, and the more expensive it is accordingly." In terms of price, the second price of GSK that has been sold for four months is RMB 580 for sirish, and the fourth price of jiadaxiu is RMB 798 for moshadong The price of a single unit is nearly 40% higher From the perspective of scope of application, GSK products are suitable for 9 to 25 years old, while MSD products are suitable for 20 to 45 years old, that is to say, the age range of the overlapping competition groups is 20 to 25 years old Age also relates to spending power and vaccination effectiveness According to the recommendation of the World Health Organization, the main vaccinated population of cervical cancer vaccine is 9-13-year-old women, and the secondary vaccinated population is larger female teenagers and young women However, although the effectiveness of vaccination will be weakened with the increase of age, the payment ability of the elderly is relatively strong From the perspective of market opportunities, the listing time of GSK's Hirsch in the mainland market is about five months earlier than that of jiadaxiu On July 31, Hirsch went public Soon after that, GSK joined hands with Ali to seize the market According to GSK, the cooperation project covers more than 150 community health service centers in 40 cities - it is expected that by the end of this year, it will cover 1500 community health service centers in hundreds of cities including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Nanjing and Wuhan Mosadon, who has lost the opportunity of market, is not willing to show weakness and join hands with Zhifei biology MSD and Zhifei biology signed an agreement Both parties agreed that after the listing of MSD's four price HPV vaccine, Zhifei biology will be responsible for the import, promotion and sales of the product in mainland China Zhifei biology has the exclusive agency right for the product It is understood that at present, Harbin, Nanjing, Zhengzhou and other places have successively started the appointment vaccination of four price HPV vaccine ▍ new players will enter the cervical cancer stadium at the latest With the sound of firecrackers in the new year, the war between GSK and MSD in the HPV market will start Many local pharmaceutical companies are also seeking a share At present, 11 pharmaceutical companies in China have submitted clinical applications for HPV vaccine, including three vaccines with four prices, one vaccine with six prices, four vaccines with nine prices, and the nine vaccines of MSD are also under review It's not hard to imagine that a price war is inevitable if the local drug companies want to "control people" According to the market forecast, the fastest HPV vaccine of Shanghai Zerun (owned by Watson) will not be available until 2019, when GSK and MSD are in front, the market situation may not be too optimistic However, fortunately, according to the analysis of the insiders, it is a trend that the market will continue to expand According to the data of cutting-edge industry research institute, if the penetration rate of HPV vaccine in the Chinese market reaches 5%, the market capacity of domestic HPV vaccine will reach 32.2 billion, with great space In addition, in addition to a wide range of adult vaccine injection needs, some regional governments also intend to bear the burden of class II vaccine With the increasing financial burden of the government departments, it should be a national trend for the second class vaccine to be included in the immunization program In addition to the policy factors, the reality that consumers' health awareness and consumption ability are rising can not be ignored Previously, media reported that Hong Kong's nine price cervical cancer vaccine was in short supply and out of stock After all, cervical cancer is the only cancer in the world that has been cracked, and vaccination can play a preventive role With the expansion of cervical cancer vaccine market, a battle of "chasing the Central Plains" is inevitable.